Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with ...

Get the detailed quarterly/annual income statement for Vivani Medical, Inc. (VANI). Find out the revenue, expenses and profit or loss over the last fiscal year.

ALAMEDA, Calif., November 13, 2024--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported ...

--Vivani Medical, Inc., a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced promising preclinical data for NPM-139, its subdermal ...

Vivani Medical, Inc. VANI recently announced the filing of a Form 10 registration statement with the U.S. Securities and Exchange Commission (“SEC”), marking the first formal step toward ...

Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of chronic weight management in obese or overweight ...

Vivani Medical unveils preclinical data on NPM-115, a twice-yearly exenatide subdermal implant for weight loss. Achieving a 20% reduction in high-fat diet-induced obese mice, comparable to Novo ...

Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight subjects.

Vivani Medical shares surged more than five-fold in early trading on Wednesday after the drug developer said its experimental under-the-skin drug implant helped reduce weight in obese mice in a ...

Vivani’s Chief Executive Officer Adam Mendelsohn, Ph.D., stated, “We made significant progress advancing our proprietary GLP-1 implants for obesity and chronic weight management in the third ...